Compare ECCC & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECCC | CADL |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 280.3M |
| IPO Year | N/A | 2021 |
| Metric | ECCC | CADL |
|---|---|---|
| Price | $24.58 | $4.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.71 |
| AVG Volume (30 Days) | 5.9K | ★ 1.3M |
| Earning Date | N/A | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.87 | $4.25 |
| 52 Week High | $25.00 | $8.66 |
| Indicator | ECCC | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 57.53 | 45.28 |
| Support Level | $23.14 | $4.58 |
| Resistance Level | $24.87 | $5.42 |
| Average True Range (ATR) | 0.31 | 0.25 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 91.80 | 53.33 |
Eagle Point Credit Co Inc. is an externally managed, non-diversified closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective of capital appreciation. The Company seeks to achieve its investment objectives by investing in equity and junior debt tranches of collateralized loan obligations ("CLOs") collateralized by a portfolio consisting of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors. The Company intends to operate so as to qualify to be taxed as a regulated investment company.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.